Baxiva

We are Baxiva, a biotechnology startup developing next-generation glycoconjugate vaccines to combat bacterial infections. Our mission is to address urgent global health needs by targeting pathogens with high clinical burden and rising antimicrobial resistance. Our lead program focuses on preventing urinary tract and invasive infections caused by Escherichia coli—the world’s leading cause of antibiotic-resistant infections.